drugset / Trial / NCT02245087

Eliminate Coronary Artery Disease

NCT02245087

Phase 2 Terminated 28 enrolled University Health Network, Toronto
RandomizedParallel-groupOpen-labelPrevention

Summary

The purpose of this study is to determine whether pharmacologic lowering of low density lipoprotein cholesterol (LDL), initiated in healthy young to middle aged adults can eliminate or markedly reduce the composite endpoint of incident all cause mortality, myocardial infarction, stroke or coronary revascularization.

Timeline

Start
2014-08
Primary completion
2019-09
Completion
2019-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Atorvastatin Small molecule 20 mg